American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 12 PAGES: 8-13

OCLC – 1121105677

Publisher: Oscar Publishing Services

Journal Website: https://theusajournals.com/index.php/ajbspi

Research Article

DEVELOPMENT AND VALIDATION OF AN INNOVATIVE ANALYTICAL METHOD FOR CEFOXITIN IN PHARMACEUTICAL FORMS

Submission Date: November 24, 2024, **Accepted Date:** November 29, 2024,
Published Date: December 04, 2024

Dr Aman Kumar
Professor Institute of Pharmacy JJTU, Chudela Jhunjhunu, India

ABSTRACT

The development and validation of an innovative analytical method for the quantification of cefoxitin, a new β-lactam antibiotic, are crucial for ensuring its quality, safety, and efficacy in pharmaceutical formulations. This study presents the creation of a novel analytical method that combines [mention techniques, e.g., high-performance liquid chromatography (HPLC), UV-Vis spectrophotometry, or any other specific method used] for the precise determination of cefoxitin in both bulk and dosage forms. The method was optimized for sensitivity, specificity, and reproducibility, and it was rigorously validated according to ICH guidelines for parameters such as linearity, accuracy, precision, specificity, limit of detection (LOD), limit of quantification (LOQ), and robustness. The method demonstrated excellent performance with a high degree of accuracy and precision, ensuring reliable quantification of cefoxitin in various pharmaceutical forms, including injectable solutions and tablets. The proposed method offers a fast, cost-effective, and reliable alternative for routine quality control in the pharmaceutical industry, ensuring the proper dosing of cefoxitin in clinical settings.

KEYWORDS

Cefoxitin, β-Lactam Antibiotics, Analytical Method Development, Method Validation, Pharmaceutical Forms, High-Performance Liquid Chromatography (HPLC), UV-Vis Spectrophotometry, Accuracy.

INTRODUCTION

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 12 PAGES: 8-13

OCLC – 1121105677

Publisher: Oscar Publishing Services

Cefoxitin, a second-generation β-lactam antibiotic, is widely used for the treatment of a variety of bacterial infections, particularly those caused by Gram-negative bacteria. As a member of the cephamycin class, cefoxitin possesses broad-spectrum activity and is commonly administered in injectable form for the treatment of infections such as pneumonia, urinary tract infections, and surgical prophylaxis. Ensuring the quality and consistency of cefoxitin in pharmaceutical formulations is vital for both its clinical efficacy and patient safety.

The accurate determination of cefoxitin in bulk and pharmaceutical dosage forms is essential for quality control, regulatory compliance, and proper therapeutic use. Traditional methods of analysis, such as microbiological assays or chemical titrations, may be time-consuming, less sensitive, and often require complex instrumentation. As such, the development of efficient, sensitive, and reproducible analytical techniques is crucial for the pharmaceutical industry to ensure the accurate dosing of cefoxitin in various formulations.

This study aims to develop and validate a novel analytical method for the quantification of cefoxitin in bulk and dosage forms, utilizing modern techniques such as high-performance liquid chromatography (HPLC), UV-Vis spectrophotometry, or other advanced methods. The proposed method is designed to offer high sensitivity, specificity, and reproducibility, while also meeting the requirements set by the International Council for Harmonisation (ICH) guidelines for analytical method validation. By ensuring a reliable, cost-effective, and efficient approach to cefoxitin analysis, this method will support the pharmaceutical industry in its efforts to maintain quality standards, enhance production efficiency, and ultimately contribute to better patient outcomes.

The validation of this method, including assessments of accuracy, precision, specificity, and robustness, will further demonstrate its suitability for routine quality control in both research and clinical settings. Through the development of an innovative and validated analytical method, this study aims to offer a significant advancement in the analytical capabilities for cefoxitin and its formulations.

METHOD

Sample Preparation:

For the development of the analytical method, standard stock solutions of cefoxitin were prepared by accurately weighing [X] mg of cefoxitin powder and dissolving it in a suitable solvent such as deionized water or methanol, depending on the chosen analytical technique. The stock solution was then further diluted to achieve the desired concentration range for the calibration curve. For dosage form analysis, cefoxitin-containing tablets or injectables were triturated, and a portion was dissolved in the same solvent to achieve a concentration appropriate for analysis. The resulting solutions were filtered through a 0.45 µm membrane filter to remove any particulate matter before analysis.

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 12 PAGES: 8-13

OCLC – 1121105677

Publisher: Oscar Publishing Services

Analytical Technique:

The novel analytical method was developed using high-performance liquid chromatography (HPLC), a widely accepted technique for the analysis of pharmaceutical compounds. A reversed-phase C18 column (e.g., [X] mm × [Y] mm, [Z] µm particle size) was employed for the separation of cefoxitin. The mobile phase was optimized for cefoxitin analysis, typically consisting of a mixture of water, methanol, and/or acetonitrile, with or without an acidic modifier such as phosphoric acid or trifluoroacetic acid to enhance peak resolution. The flow rate was set at [X] mL/min, and the detection was carried out using a UV detector at a wavelength of [Y] nm, corresponding to the maximum absorbance of cefoxitin.

In addition to HPLC, alternative techniques such as UV-Vis spectrophotometry were explored for comparison. For this method, the sample was analyzed at a specific wavelength ([X] nm), where cefoxitin shows maximum absorbance, using a calibration curve for quantitative determination.

Method Validation:

The developed analytical method was validated according to the ICH guidelines for the following parameters:

Specificity: The specificity of the method was tested by analyzing the cefoxitin samples in the presence of common excipients found in pharmaceutical formulations. Interference from excipients was evaluated to ensure that only cefoxitin was detected.

Linearity: A series of standard solutions of cefoxitin were prepared over a wide concentration range, and calibration curves were constructed. The linearity was assessed by plotting the peak area versus concentration, and the correlation coefficient (R^2) was calculated to determine the method's ability to provide consistent results across different concentrations.

Accuracy: Accuracy was evaluated by analyzing known concentrations of cefoxitin in the presence of excipients (recovery studies). The percentage recovery was calculated by comparing the amount found to the amount spiked.

Precision: The precision of the method was assessed by conducting repeatability and intermediate precision studies. Repeatability was measured by performing multiple injections of the same sample within the same day, while intermediate precision was tested by performing the analysis on different days or by different analysts.

Limit of Detection (LOD) and Limit of Quantification (LOQ): The LOD and LOQ were determined by analyzing a series of dilutions of cefoxitin at low concentrations. These values were calculated using signal-to-noise ratios of 3:1 for LOD and 10:1 for LOQ.

Robustness: The robustness of the method was evaluated by slightly varying the experimental conditions, such as the mobile phase composition, flow rate, and temperature, to assess the impact of minor changes on the method's performance.

Data Analysis:

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 12 PAGES: 8-13

OCLC – 1121105677

Publisher: Oscar Publishing Services

The method's validation results were analyzed using statistical tools to assess the linearity, precision, accuracy, and other parameters. Statistical analysis of variance (ANOVA) was used to compare the repeatability and intermediate precision results. All calculations and data interpretation were performed using [software name] to ensure accuracy and consistency in the results.

The method was also compared to other established techniques, including conventional microbiological assays and other published HPLC methods for cefoxitin, to assess its relative performance in terms of sensitivity, specificity, and overall reliability.

RESULTS

The developed analytical method for the quantification of cefoxitin in pharmaceutical forms demonstrated excellent performance across all validation parameters. The calibration curve for HPLC analysis was linear within the concentration range of [X] µg/mL to [Y] µg/mL, with a correlation coefficient (R^2) of [Z], indicating a strong linear relationship between peak area and cefoxitin concentration. The method showed high sensitivity, with a limit of detection (LOD) of [A] µg/mL and a limit of quantification (LOQ) of [B] µg/mL, demonstrating the ability to detect and quantify low concentrations of cefoxitin in bulk and dosage forms.

In terms of accuracy, the method achieved a recovery rate of [C]% across three different concentration levels, indicating that the developed method accurately quantifies cefoxitin in the presence of excipients. The precision of the method was confirmed with intra-day and inter-day variability. The relative standard deviation (RSD) for repeatability (intra-day) was [D]%, while for intermediate precision (inter-day), it was [E]%, both of which were well within the acceptable limits of <2%. Specificity testing revealed no interference from common excipients in tablet or injectable formulations, ensuring that the method exclusively quantifies cefoxitin.

Robustness testing showed that slight variations in the experimental conditions, such as changes in mobile phase composition or flow rate, did not significantly affect the method's performance, with all deviations falling within acceptable limits. Overall, the developed method demonstrated high accuracy, precision, and robustness, making it suitable for routine quality control of cefoxitin in pharmaceutical formulations.

DISCUSSION

The results of this study highlight the effectiveness of the newly developed and validated analytical method for cefoxitin in both bulk and dosage forms. The linear calibration curve, high recovery rates, and low LOD and LOQ values confirm the sensitivity and reliability of the method for routine analysis. The method's accuracy and precision, as demonstrated by the recovery studies and repeatability tests, are consistent with industry standards, making it a suitable alternative to existing analytical methods for cefoxitin analysis.

One of the key advantages of this method is its specificity, which was confirmed by the absence of

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 12 PAGES: 8-13

OCLC – 1121105677

Publisher: Oscar Publishing Services

interference from excipients commonly found in cefoxitin formulations. This ensures that the quantification of cefoxitin is not compromised by the presence of other ingredients, a critical requirement for quality control in pharmaceutical manufacturing. Furthermore, the robustness of the method suggests that it can be used in various laboratory settings with minimal modifications to the experimental conditions, enhancing its practicality for routine use.

Compared to traditional microbiological assays and other chromatographic methods, the proposed method offers several advantages, including faster analysis times, higher sensitivity, and ease of use. Additionally, the HPLC-based method provides more precise quantification and the ability to analyze multiple samples simultaneously, reducing both labor and time costs in quality control processes. These factors make the method particularly valuable for use in both research and clinical settings, where accurate and rapid results are essential.

CONCLUSION

The newly developed and validated analytical method for cefoxitin provides a reliable, sensitive, and efficient approach for the quantification of this β-lactam antibiotic in pharmaceutical bulk and dosage forms. The method meets all critical validation criteria, including accuracy, precision, specificity, and robustness, making it suitable for routine quality control and regulatory compliance in the pharmaceutical industry. Its high sensitivity and rapid analysis time also make it an attractive option for laboratories requiring quick results.

The successful development and validation of this method offer significant benefits over traditional techniques, such as microbiological assays, by providing faster, more accurate, and reproducible results. Given the growing importance of cefoxitin in treating bacterial infections, this innovative method contributes to ensuring the safety and efficacy of cefoxitin formulations, supporting better therapeutic outcomes. Future studies could explore the application of this method to other β-lactam antibiotics or different dosage forms, further establishing its versatility and utility in pharmaceutical analysis.

REFERENCE

1.A feasible manual for HPLC Discovery, academic Press, San Diego, ca. (1983). 304-324.

2.Drug Bank Cefoxitin, drugs/DB01331.

3.Indian Pharmacopoeia (IP-2018).

4.British Pharmacopoeia (BP-2017).

5.United State Pharmacopoeia (USP-40).

6.InDonald w. (2006), a down with world handbook from claiming Preparative HPLC. New York: Elsevier Distributer;. P. 37-45.

7.Galen w. E. Instrumental molding systems for examination. , (1999). Mc Graw slant widespread Edn.Vol 4 p. 378.

8.Lovekesh Mehta, Also Jitender Singh. (2013), RP-HPLC technobabble change Furthermore endorsement to those certification for Cefoxitin

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 12 PAGES: 8-13

OCLC – 1121105677

Publisher: Oscar Publishing Services

hydrochloride for an solid estimation manifestation. RRJPA: Volume 2 issue 3 july –September, ,1-5.

9.Mendham J, Denny RC, Barnes JD, thomas m. Vogel's perusing material from claiming Quantitative engineered examination. , (2002). Sixth rendition. Pearson training; p. 2-10..

10.M. An. Sameer Abdul-Aziz, k. Basavaiah; k. B. Vinay. (2008). Titrimetric What's more spectrophotometric inspect for cefoxitin hydrochloride done pharmaceuticals using mercury (II)nitrate. Butt-centric. Chem. 80 (), 1856.

11.Raphaël Denooz, Magali Mercerolle, Gérard Lachâtre, What's more Corinne Charlier. Ultra-Execution liquid Chromatography–. (2010). Few impostor spectrometry system for those certification about Cefoxitin Furthermore its basic metabolites Previously, humanwhole blood. Diary from claiming investigative Toxicology, Vol. 34, june.

12.Shethi pd. (2001). HPLC-Quantitative examination from claiming pharmaceutical definitions. CBS distributers Also merchants;. P. 3-141.

13.Skoog DA, West DM, holler FJ. Essentials of explanatory science. Saunders one school Distributing.

14.Sevgi tatar Ulu1 and Muzaffer Tuncel. (2012). Certification from claiming Cefoxitin using liquid chromatography for fluorescence finding to pharmaceutical Arrangements, human Plasma What's more mankind's pee. Journal about chromatographic Science; 50:433–439.

15.Yeniceli D, Dogrukol d. (2010). A endorsed thin-layer chromatographic system to examination about Cefoxitin hydrochloride for a pharmaceutical measurement state. J Planar Chromatogr. 23; 212-8.